Leukemia Research
Volume 30, Issue 2 , Pages 178-182 , February 2006

Usefulness and prognostic impact on survival of WHO reclassification in FAB low risk myelodyplastic syndromes

Received 26 May 2005 ,Accepted 26 June 2005.

References 

  1. Bennett JM, Catovsky D, Daniel MT, Flandrin G, Galton DA, Gralnick HR, et al. Proposals for the classification of the myelodysplastic syndromes. Br J Haematol. 1982;51:189–199
  2. Vallespi T, Torrabadella M, Julia A, Irriguible D, Jaen A, Acebedo G, et al. Myelodysplastic syndromes: a study of 101 cases according to the FAB classification. Br J Haematol. 1985;61:83–92
  3. Germing U, Gattermann N, Strupp C, Aivado M, Aul C. Validation of the WHO proposals for a new classification of primary myelodysplastic syndromes: a retrospective analysis of 1600 patients. Leuk Res. 2000;24:983–992
  4. Harris NL, Jaffe ES, Diebold J, Flandrin G, Muller-Hermelink HK, Vardiman J, et al. World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues: report of the Clinical Advisory Committee meeting-Airlie House, Virginia, November 1997. J Clin Oncol 1999;17:3835–49.
  5. Rosati S, Mick R, Xu F, Stonys E, Le Beau MM, Larson R, et al. Refractory cytopenia with multilineage dysplasia: further characterization of an ‘unclassifiable’ myelodysplastic syndrome. Leukemia. 1996;10:20–26
  6. Cermak J, Michalova K, Brezinova J, Zemanova Z. A prognostic impact of separation of refractory cytopenia with multilineage dysplasia and 5q- syndrome from refractory anemia in primary myelodysplastic syndrome. Leuk Res. 2003;27:221–229
  7. Howe RB, Porwit-MacDonald A, Wanat R, Tehranchi R, Hellstrom-Lindberg E. The WHO classification of MDS does make a difference. Blood. 2004;103:3265–3270
  8. Matsuda A, Germing U. Refractory anemia (RA) and refractory cytopenia with multilineage dysplasia (RCMD) in WHO classification: comparison between Japanese and German cases. Rinsho Ketsueki. 2004;45:268–273
  9. Nosslinger T, Reisner R, Koller E, Gruner H, Tuchler H, Nowotny H, et al. Myelodysplastic syndromes, from French–American–British to World Health Organization: comparison of classifications on 431 unselected patients from a single institution. Blood. 2001;98:2935–2941
  10. Giagounidis AA, Germing U, Haase S, Hildebrandt B, Schlegelberger B, Schoch C, et al. Clinical, morphological, cytogenetic, and prognostic features of patients with myelodysplastic syndromes and del(5q) including band q31. Leukemia. 2004;18:113–119
  11. Lewis S, Oscier D, Boultwood J, Ross F, Fitchett M, Rack K, et al. Hematological features of patients with myelodysplastic syndromes associated with a chromosome 5q deletion. Am J Hematol. 1995;49:194–200
  12. Vardiman JW, Harris NL, Brunning RD. The World Health Organization (WHO) classification of the myeloid neoplasms. Blood. 2002;100:2292–2302
  13. Bennett JM, Brunning RD, Vardiman JW. Myelodysplastic syndromes: from French–American–British to World Health Organization: a commentary. Blood. 2002;99:3074–3075
  14. In:  Mitelman F editors. ISCN: an international system for human cytogenetic nomenclature. Karger: Basel; 1995;
  15. Greenberg P, Cox C, LeBeau MM, Fenaux P, Morel P, Sanz G, et al. International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood. 1997;89:2079–2088
  16. Mufti GJ, Stevens JR, Oscier DG, Hamblin TJ, Machin D. Myelodysplastic syndromes: a scoring system with prognostic significance. Br J Haematol. 1985;59:425–433
  17. Sanz GF, Sanz MA, Vallespi T, Canizo MC, Torrabadella M, Garcia S, et al. Two regression models and a scoring system for predicting survival and planning treatment in myelodysplastic syndromes: a multivariate analysis of prognostic factors in 370 patients. Blood. 1989;74:395–408
  18. Nosslinger T, Reisner R, Koller E, Gruner H, Tuchler H, Nowotny H, et al. Myelodysplastic syndromes, from French–American–British to World Health Organization: comparison of classifications on 431 unselected patients from a single institution. Blood. 2001;98:2935–2941
  19. Dunkley SM, Manoharan A, Kwan YL. Myelodysplastic syndromes: prognostic significance of multilineage dysplasia in patients with refractory anemia or refractory anemia with ringed sideroblasts. Blood. 2002;99:3870–3871
  20. Cermak J, Vitek A, Michalova K. Combined stratification of refractory anemia according to both WHO and IPSS criteria has a prognostic impact and improves identification of patients who may benefit from stem cell transplantation. Leuk Res. 2004;28:551–557
  21. Gattermann N, Aul C, Schneider W. Two types of acquired idiopathic sideroblastic anaemia (AISA). Br J Haematol. 1990;74:45–52
  22. Garand R, Gardais J, Bizet M, Bremond JL, Accard F, Callat MP, et al. Heterogeneity of acquired idiopathic sideroblastic anaemia (AISA). Leuk Res. 1992;16:463–468

PII: S0145-2126(05)00257-2

doi: 10.1016/j.leukres.2005.06.015

Leukemia Research
Volume 30, Issue 2 , Pages 178-182 , February 2006

Article Tools